乌司奴单抗与肿瘤坏死因子抑制剂对附着点炎疗效比较:附着点清除在银屑病关节炎(ECLIPSA)研究结果
ECLIPSA 是一项前瞻性随机对照开放标签研究,纳入活动性附着点炎的银屑病关节炎患者,1:1 随机接受乌司奴单抗或肿瘤坏死因子抑制剂。24 周时乌司奴单抗组 73.9% 与 TNFi 组 41.7% 达到 SPARCC=0(p=0.018),附着点炎和银屑病皮损应答乌司奴单抗更优(p=0.007、p=0.030),关节炎无差异(p=0.95)。
要点
- 24 周附着点完全清除率乌司奴单抗组 73.9% vs TNFi 组 41.7%(p=0.018)。
- 附着点炎(p=0.007)与银屑病皮损(p=0.030)乌司奴单抗优于 TNFi。
- 关节炎应答两组无显著差异(p=0.95)。
核心结论
- p40-IL-12/IL-23 抑制在附着点清除方面优于 TNFi。
研究设计与样本
- ECLIPSA 为前瞻性随机对照开放标签研究,51 例银屑病关节炎患者筛查,47 例入组(乌司奴单抗组 23 例、TNFi 组 24 例),46 例完成研究。
主要发现
- 基线平均 SPARCC 指数乌司奴单抗组 4.8±2.6、TNFi 组 3.5±2.3,两组无显著差异。
- 24 周达到主要终点(SPARCC=0)者乌司奴单抗组 73.9%、TNFi 组 41.7%(p=0.018)。
- 附着点炎应答乌司奴单抗优于 TNFi(p=0.007)。
- 银屑病皮损应答乌司奴单抗优于 TNFi(p=0.030)。
- 关节炎应答两组无显著差异(p=0.95)。
关键数值与推荐
- 主要终点为 24 周 SPARCC 指数等于 0 定义的附着点完全清除。
临床怎么用
- 作者认为未来银屑病关节炎的分层治疗可能考虑以附着点炎存在与否作为不同细胞因子阻断方案应答的区分因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To date, all studies addressing on anti-inflammatory drugs in PsA have been carried out in psoriatic arthritis (PsA) patients with polyarticular disease. Specific studies on enthesitis are missing. IL-23 is considered to play a central role in the development of enthesitis. We therefore speculated that therapeutic inhibition of IL-12/IL-23 is particularly effective in enthesitis-driven PsA patients. METHODS: Enthesial CLearance In PSoriatic Arthritis (ECLIPSA) is a prospective randomized-controlled open-label study. Patients with PsA with active enthesitis were randomized 1:1 to receive either ustekinumab (UST; arm 1) or tumor necrosis factor inhibitors (TNFi; arm 2). Primary endpoint was complete clearance of enthesitis, defined by Spondyloarthritis Research Consortium of Canada (SPARCC) index equal to zero at 24 weeks. RESULTS: 51 patients (UST = 25; TNFi = 26) were screened, 47 enrolled (UST = 23; TNFi = 24) and 46 completed the study. Mean ± SD SPARCC index at baseline was 4.8 ± 2.6 in the UST group and 3.5 ± 2.3 in the TNFi group with no significant difference. After 24 weeks, 73.9% of UST patients and 41.7% of TNFi patients reached the primary endpoint (SPARCC = 0) indicating clearance from enthesitis (p = 0.018). UST achieved superior responses as compared to TNFi with respect to enthesitis (p = 0.007) and psoriatic skin disease (p = 0.030) but not for arthritis (p = 0.95). CONCLUSION: These results indicate that p40-IL-12/IL-23 inhibition is superior to TNFi in the clearance of enthesitis. Future stratified therapeutic approaches in PsA patients may therefore consider the presence or absence of enthesitis as a discriminator of response between different cytokine blocking modalities.
引用
- Araujo EG, Englbrecht M, Hoepken S, et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2018. PMID: 30037432. doi:10.1016/j.semarthrit.2018.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。